Patient-Reported Outcomes in People with Type2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.

Abstract

Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide1 receptor agonist, is approved for glycaemic control for people with type2 diabetes (T2D). The SURPASS-1 to -5 clinical trials assessed the efficacy of once weekly tirzepatide (5, 10 and 15mg) versus placebo or active comparators (semaglutide 1mg, insulin degludec and insulin glargine) in T2D. We evaluated patient-reported outcomes (PROs) that measured overall quality of life (QoL), treatment satisfaction and weight-related attributes across the five SURPASS studies. PRO instruments utilised at baseline and primary timepoint (40weeks for SURPASS-1, -2 and -5; 52weeks for SURPASS-3 and -4) or early termination visit were EQ-5D-5L (SURPASS-1 to -5); Impact of Weight on Self-Perceptions (SURPASS-1 to -5); Ability to Perform Physical Activities of Daily Living (SURPASS-1 to -5); Diabetes Treatment Satisfaction Questionnaire (SURPASS-2 to -5); and Impact of Weight on Quality of Life-Lite Clinical Trials Version (SURPASS-2 only). Across all five studies at week40/52, tirzepatide improved patients' QoL measured by general health and weight-related PROs over the comparator. Generally, higher doses of tirzepatide resulted in greater increases in PRO scores. Overall, tirzepatide produced significant health and weight-related QoL improvements versus comparators in the five SURPASS studies. SURPASS-1: NCT03954834; SURPASS-2: NCT03987919; SURPASS-3: NCT03882970; SURPASS-4: NCT03730662; SURPASS-5: NCT04039503.